AIML.CN Stock Trades at C$0.035 on CNQ Exchange Today

AIML.CN stock trades at C$0.035 on the CNQ exchange today with flat performance. AI/ML Innovations Inc., a Victoria-based healthcare technology company, focuses on digital health monitoring and wearable solutions using artificial intelligence and machine learning. The stock has declined significantly over longer periods, with a 50% drop over one year and 95% decline over five years. Meyka AI rates AIML.CN with a grade of C+, suggesting a hold position. The company operates in the Medical – Healthcare Information Services industry, offering patent-pending personal health monitoring systems for caregivers, patients, and healthcare professionals.

AIML.CN Stock Price and Market Performance

AIML.CN stock currently trades at C$0.035 per share with zero change today. The stock opened at C$0.04 and has traded between C$0.035 and C$0.04 during the session. Volume stands at 312,246 shares, below the average of 403,403 shares. Over the past month, AIML.CN stock has fallen 12.5%, while the six-month decline reaches 30%. The year-to-date performance shows a 50% drop, reflecting sustained pressure on the stock. The 52-week high sits at C$0.12, while the low stands at C$0.03, indicating significant volatility. Market cap totals approximately C$5.89 million with 168.26 million shares outstanding.

Meyka AI Grade and Financial Assessment

Meyka AI rates AIML.CN with a grade of C+ and a hold recommendation. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The rating score of 1 reflects weak fundamentals across multiple dimensions. All key metrics receive strong sell recommendations, including DCF valuation, return on equity, return on assets, debt-to-equity ratio, price-to-earnings, and price-to-book ratios. The company shows negative earnings per share of -C$0.03 and a negative PE ratio of -1.17. These grades are not guaranteed and we are not financial advisors. Investors should conduct thorough research before making decisions.

AIML.CN Stock Analysis: Key Financial Metrics

AIML.CN stock faces significant financial challenges. The price-to-sales ratio stands at 46.94x, indicating expensive valuation relative to revenue. Net profit margin is deeply negative at -56.22%, showing the company loses money on every dollar of sales. Return on equity reaches -5.05%, while return on assets sits at -4.34%. The current ratio of 0.76 falls below 1.0, suggesting potential liquidity concerns. Operating cash flow per share is negative at -C$0.021, and free cash flow per share is -C$0.021. Track AIML.CN on Meyka for real-time updates on these metrics. The company’s debt-to-equity ratio of 0.72 indicates moderate leverage, though profitability issues overshadow this concern.

Market Sentiment and Trading Activity

Technical indicators show mixed signals for AIML.CN stock. The relative strength index (RSI) reads 46.47, suggesting neutral momentum without clear overbought or oversold conditions. The commodity channel index (CCI) at 147.37 indicates overbought territory, while stochastic %K reaches 66.67. The moving average envelope slope is negative at -0.48, reflecting downward pressure. Volume remains below average at 312,246 shares versus 403,403 average daily volume. The on-balance volume (OBV) is negative at -9,331, suggesting selling pressure. Money flow index (MFI) at 64.79 indicates strong buying interest despite negative fundamentals. Rate of change shows -12.5% decline over recent periods.

Healthcare Sector Context and Industry Position

The Healthcare sector shows mixed performance with a market cap of C$856.41 billion across 29 companies. The sector’s average PE ratio is 16.4x, while AIML.CN trades at a negative PE. Healthcare sector average ROE stands at 3.65%, significantly outperforming AIML.CN’s -5.05%. The industry average price-to-sales ratio is 314.21x, though this reflects sector-wide challenges. AIML.CN operates in Medical – Healthcare Information Services, competing with larger, more profitable players. The sector’s average current ratio of 1.51 exceeds AIML.CN’s 0.76, highlighting liquidity concerns. Competitor analysis shows AIML.CN lags peers in profitability and operational efficiency metrics.

Long-Term Price Trends and Forecast Outlook

AIML.CN stock has experienced severe long-term declines. The three-year loss reaches 69.57%, while the five-year decline totals 95.07%. The ten-year loss stands at 76.67%, and the all-time decline from peak reaches 93%. Meyka AI’s forecast model projects a yearly price target of C$0.0217, compared to the current C$0.035 price. This implies a downside of approximately 38% from current levels. The monthly forecast suggests C$0.02, indicating near-term weakness. These forecasts are model-based projections and not guarantees. The company’s inability to achieve profitability and negative cash flows raise concerns about long-term viability. Investors should carefully evaluate turnaround prospects before committing capital.

Final Thoughts

AIML.CN stock presents a challenging investment profile with significant headwinds. Trading at C$0.035 on the CNQ exchange, the stock faces deep profitability challenges, negative cash flows, and liquidity concerns. Meyka AI’s C+ grade with hold recommendation reflects weak fundamentals across valuation, profitability, and operational metrics. The company’s -56% net margin and negative ROE indicate structural business challenges beyond temporary market conditions. Long-term price trends show devastating declines, with the stock down 95% over five years and 93% from all-time highs. While the healthcare technology sector offers growth potential, AIML.CN has failed to capitalize on AI and machine learning trends. The forecast model projects further downside to C$0.0217. Investors should demand clear evidence of operational turnaround and path to profitability before considering positions. Risk tolerance must be extremely high given the company’s financial distress and uncertain recovery timeline.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.